PROFESS trial to be published in NEJM in June will show that Boehringer Ingelheim's Aggrenox was not "non-inferior" to Bristol Myers and Sanofi's Plavix for prevention of a second stroke. Data presented in Europe, so public, but not well-known. Betting BMY will see a short term gain when NEJM article comes out. (I actually don't think Plavix sales will increase much, but I think people will think they will.)